EG19860A - Enzymatic resolution of endo - bicyclo (2,2,1) heptan -2-ol and derived pharmaceutical agents - Google Patents

Enzymatic resolution of endo - bicyclo (2,2,1) heptan -2-ol and derived pharmaceutical agents

Info

Publication number
EG19860A
EG19860A EG67090A EG67090A EG19860A EG 19860 A EG19860 A EG 19860A EG 67090 A EG67090 A EG 67090A EG 67090 A EG67090 A EG 67090A EG 19860 A EG19860 A EG 19860A
Authority
EG
Egypt
Prior art keywords
endo
heptan
bicyclo
pharmaceutical agents
enzymatic resolution
Prior art date
Application number
EG67090A
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of EG19860A publication Critical patent/EG19860A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C35/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C35/22—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/10—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/37—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by etherified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
    • C07C45/71—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
    • C07C47/575—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
    • C12P41/003—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions
    • C12P41/004—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions by esterification of alcohol- or thiol groups in the enantiomers or the inverse reaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/02—Preparation of oxygen-containing organic compounds containing a hydroxy group

Abstract

A mammalian pancreatic lipase mediated transesterification method for the optical resolution of endo-norborneol.
EG67090A 1989-11-13 1990-11-11 Enzymatic resolution of endo - bicyclo (2,2,1) heptan -2-ol and derived pharmaceutical agents EG19860A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1989/005228 WO1991007501A1 (en) 1989-11-13 1989-11-13 Enzymatic resolution of endo-bicyclo[2.2.1]heptan-2-ol and derived pharmaceutical agents

Publications (1)

Publication Number Publication Date
EG19860A true EG19860A (en) 1996-03-31

Family

ID=22215375

Family Applications (1)

Application Number Title Priority Date Filing Date
EG67090A EG19860A (en) 1989-11-13 1990-11-11 Enzymatic resolution of endo - bicyclo (2,2,1) heptan -2-ol and derived pharmaceutical agents

Country Status (27)

Country Link
EP (2) EP0428302B1 (en)
JP (1) JPH06104661B2 (en)
KR (1) KR930004654B1 (en)
CN (1) CN1040423C (en)
AT (1) ATE158577T1 (en)
AU (3) AU633157B2 (en)
CA (1) CA2029705C (en)
CZ (2) CZ280006B6 (en)
DE (1) DE69031487T2 (en)
DK (1) DK0428302T3 (en)
EG (1) EG19860A (en)
ES (1) ES2107420T3 (en)
FI (1) FI105106B (en)
GR (1) GR3025196T3 (en)
HU (2) HU215441B (en)
IE (2) IE904059A1 (en)
IL (5) IL110568A (en)
MY (1) MY104517A (en)
NO (1) NO304838B1 (en)
NZ (1) NZ236037A (en)
PH (1) PH30255A (en)
PL (4) PL164176B1 (en)
PT (1) PT95855B (en)
RU (1) RU2104306C1 (en)
WO (1) WO1991007501A1 (en)
YU (1) YU48413B (en)
ZA (1) ZA909044B (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2104306C1 (en) * 1989-11-13 1998-02-10 Пфайзер Инк. Method of synthesis of optically active (2s)- or (2r)-endo-bicyclo-[2,2,1]-heptane-2-ol, method of synthesis of 5-(3-[(2r)-exo-bicyclo-[2,2,1]-hept-2-yloxy]-4-methoxyphenyl)- -3,4,5,6-tetrahydropyrimidine-2(1h)-one
US5124455A (en) * 1990-08-08 1992-06-23 American Home Products Corporation Oxime-carbamates and oxime-carbonates as bronchodilators and anti-inflammatory agents
IE71647B1 (en) 1991-01-28 1997-02-26 Rhone Poulenc Rorer Ltd Benzamide derivatives
JP3231325B2 (en) * 1991-12-06 2001-11-19 塩野義製薬株式会社 Method for producing optically active norborneol
CA2400368A1 (en) * 1992-12-02 1994-06-09 Allen J. Duplantier Catechol diethers as selective pde iv inhibitors
US5814651A (en) * 1992-12-02 1998-09-29 Pfizer Inc. Catechol diethers as selective PDEIV inhibitors
JP3431204B2 (en) * 1993-04-22 2003-07-28 塩野義製薬株式会社 Norbornane type ester hydrolase
CN1041436C (en) * 1993-05-07 1998-12-30 佛山市制药一厂 Prescription for stabilizator of rheumatism-traumatic medicinal liquor
US5482944A (en) * 1993-07-13 1996-01-09 Pfizer Inc. Pyrimidones and imidazolinones for treatment of shock
JPH1142095A (en) * 1997-07-25 1999-02-16 Chisso Corp New production method of oxodicyclopentadiene
KR100479019B1 (en) * 1998-05-22 2005-08-29 씨제이 주식회사 Catethcol hydrazone derivatives, process for preparing the same and pharmaceutical composition containing the same
SK287231B6 (en) 1999-08-21 2010-04-07 Nycomed Gmbh Medicament comprising a PDE inhibitor and a beta2 adrenoreceptor agonist
WO2003002511A1 (en) 2001-06-29 2003-01-09 Nikken Chemicals Co., Ltd. Cycloalkenone derivative
ES2194588B1 (en) * 2001-07-13 2004-10-16 Astur Pharma S.A. OPTICALLY PURE PAROXETINE PRECURSORS.
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
BRPI0409229A (en) 2003-04-01 2006-03-28 Applied Research Systems phosphodiesterase inhibitors in infertility
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA2688161C (en) 2007-06-04 2020-10-20 Kunwar Shailubhai Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
ES2522968T3 (en) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
ES2624828T3 (en) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer and others
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CN108676076A (en) 2011-03-01 2018-10-19 辛纳吉制药公司 The method for preparing guanosine cyclic mono-phosphate agonist
WO2014131024A2 (en) 2013-02-25 2014-08-28 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
US9486494B2 (en) 2013-03-15 2016-11-08 Synergy Pharmaceuticals, Inc. Compositions useful for the treatment of gastrointestinal disorders
JP6606491B2 (en) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド Ultra high purity agonist of guanylate cyclase C, method for producing and using the same
MX2016001714A (en) 2013-08-09 2016-10-03 Ardelyx Inc Compounds and methods for inhibiting phosphate transport.
WO2020237096A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261995A (en) * 1979-08-31 1981-04-14 Syntex (U.S.A.) Inc. 4-Phenyl-and 5-phenyl-1,4,5,6-tetrahydropyrimidine derivatives
US4732853A (en) * 1984-11-21 1988-03-22 President And Fellows Of Harvard College Method of making chiral epoxy alcohols
WO1987006576A1 (en) * 1986-04-29 1987-11-05 Pfizer Inc. Calcium independent camp phosphodiesterase inhibitor antidepressant
RU2104306C1 (en) * 1989-11-13 1998-02-10 Пфайзер Инк. Method of synthesis of optically active (2s)- or (2r)-endo-bicyclo-[2,2,1]-heptane-2-ol, method of synthesis of 5-(3-[(2r)-exo-bicyclo-[2,2,1]-hept-2-yloxy]-4-methoxyphenyl)- -3,4,5,6-tetrahydropyrimidine-2(1h)-one

Also Published As

Publication number Publication date
PL292069A1 (en) 1992-04-21
CA2029705A1 (en) 1991-05-14
ATE158577T1 (en) 1997-10-15
CZ124092A3 (en) 1995-04-12
KR930004654B1 (en) 1993-06-02
CZ560990A3 (en) 1995-04-12
IL96261A0 (en) 1991-08-16
CN1040423C (en) 1998-10-28
WO1991007501A1 (en) 1991-05-30
ES2107420T3 (en) 1997-12-01
FI105106B (en) 2000-06-15
PH30255A (en) 1997-02-05
EP0428302A3 (en) 1992-05-13
EP0801135A1 (en) 1997-10-15
NO921876L (en) 1992-07-10
CZ280006B6 (en) 1995-09-13
NO921876D0 (en) 1992-05-12
IL110564A0 (en) 1994-11-11
DE69031487T2 (en) 1998-02-05
EP0428302A2 (en) 1991-05-22
YU48413B (en) 1998-07-10
IE904059A1 (en) 1991-05-22
HU9802988D0 (en) 1999-11-29
PT95855A (en) 1991-09-13
EP0428302B1 (en) 1997-09-24
GR3025196T3 (en) 1998-02-27
HUT64604A (en) 1994-01-28
PL164457B1 (en) 1994-07-29
PL164202B1 (en) 1994-06-30
AU3292093A (en) 1993-04-22
IL110568A0 (en) 1994-11-11
MY104517A (en) 1994-04-30
FI922142A0 (en) 1992-05-12
CZ280011B6 (en) 1995-09-13
PL165132B1 (en) 1994-11-30
PL292070A1 (en) 1992-04-21
DK0428302T3 (en) 1997-10-13
AU633157B2 (en) 1993-01-21
AU645449B2 (en) 1994-01-13
IL96261A (en) 1996-12-05
AU6653590A (en) 1991-05-16
FI922142A (en) 1992-05-12
CN1051905A (en) 1991-06-05
JPH06104661B2 (en) 1994-12-21
NO304838B1 (en) 1999-02-22
HU215441B (en) 1999-04-28
PL287727A1 (en) 1992-02-24
AU3197993A (en) 1993-04-22
IE980174A1 (en) 2000-02-23
HU220962B1 (en) 2002-07-29
ZA909044B (en) 1992-06-24
YU214290A (en) 1992-12-21
DE69031487D1 (en) 1997-10-30
IL110568A (en) 1995-10-31
RU2104306C1 (en) 1998-02-10
PT95855B (en) 1998-01-30
CA2029705C (en) 1998-11-24
NZ236037A (en) 1992-08-26
PL164176B1 (en) 1994-06-30
IL110564A (en) 1998-03-10
JPH03173871A (en) 1991-07-29
KR910009622A (en) 1991-06-28

Similar Documents

Publication Publication Date Title
EG19860A (en) Enzymatic resolution of endo - bicyclo (2,2,1) heptan -2-ol and derived pharmaceutical agents
AU1935088A (en) Laser angioplasty
AU2827989A (en) Control system and method for improved laser angioplasty
AU6881791A (en) Mammalian pancreatic cholesterol esterase
AU638916B2 (en) Method for engraving solid articles with laser beams and the articles produced
AU4061289A (en) An amplification assay for hydrolase enzymes
AU6251790A (en) Focused light source and method
AU7468894A (en) Process for the enzymatic preparation of optically active n-substituted-3-pyrrolidinol
AU5364390A (en) Method for the production of amidase enzyme
AU2409088A (en) Enzyme assay method
AU5632590A (en) Method of inactivating lipase
IE881991L (en) Homocyclostatine and cyclostatine containing polypeptides as¹antihypertensive agents
AU7166991A (en) Process for racemization of optically active arylethanolamines
AU1077688A (en) Modified fibrinolytic enzymes
IL88716A (en) Process for the enzymatic hydrolysis of -aminoadipinylmonoamino compounds with -glutamyltranspeptidase and the novel enzyme therefor
CS396287A1 (en) Method of display on laser's focusing screen
MX9802380A (en) SHORT FORMS OF CHEMOKINE 'beta'-8